|
 Bruce G. Bender, Ph.D
Dr. Bruce Bender is Head of the Division of Pediatric Behavioral Health at the National Jewish Medical and Research Center and Professor of Psychiatry at the University of Colorado School of Medicine, both in Denver. His research interests include psychological stress related to chronic illness, the behaviors that moderate asthma, and psychological disorders that undermine adherence.
Dr. Bender has also conducted research designed to examine the incidence and correlates of cognitive impairment in children with asthma, which has led to a series of studies on the neuropsychological side effects of medications used to treat allergies and asthma. More recently, he has begun a program of research into sleep disorders in patients with atopic dermatitis and asthma.
Dr. Bender is the author of papers for peer-reviewed journals such as Journal of Allergy and Clinical Immunology; Annals of Allergy, Asthma and Immunology; Archives of Pediatrics and Adolescent Medicine; Pediatrics; and Current Opinion in Pediatrics. He is a member of the American Academy of Allergy, Asthma, and Immunology and the American Thoracic Society; and is Chair of the Behavioral Science Assembly of the latter. He received his doctorate from the University of Wisconsin in Madison and completed his fellowship training at the University of Colorado Health Sciences Center.
Joshua S. Benner, Pharm.D., Sc.D
Joshua S. Benner, Pharm.D., Sc.D., is Director of Health Economics with ValueMedics Research, LLC, a health care research and consulting firm in Arlington, Virginia. He leads the design and analysis of outcomes research projects including prospective trials, retrospective database analyses, and economic modeling.
Dr. Benner has been an investigator on numerous longitudinal studies regarding the patterns and predictors of patient compliance, the clinical and economic outcomes of non-compliance, and the cost-effectiveness of compliance-enhancing interventions. He has worked extensively in the therapeutic areas of dyslipidemia, Parkinson's disease, hypertension, and HIV/AIDS. Dr. Benner's work has been published in the Journal of the American Medical Association (JAMA), Controlled Clinical Trials, Journal of General Internal Medicine, Pharmacoeconomics, and other peer-reviewed journals.
Dr. Benner is a member of the Academy of Managed Care Pharmacy, the International Society for Pharmacoeconomics and Outcomes Research, the International Society for Pharmacoepidemiology, and the Society for Medical Decision Making.
He received his doctor of pharmacy degree from Drake University and his master's and doctoral degrees in health policy and management from the Harvard University School of Public Health.
Joyce Cramer
Ms. Cramer is a Lecturer in Psychiatry and Associate in Research (Neurology) at Yale University School of Medicine. During several decades of involvement in clinical trials, Ms. Cramer developed methods for the evaluation of drug efficacy and adverse effects, as well as study design and management.
These issues led to her interests in medication adherence, quality of life, and recruitment of patients for clinical trials. She is project director for a multi-center clinical trial, which includes pharmacoeconomic as well as clinical endpoints.
In addition, Ms. Cramer has contributed to five books and more than 125 article and book chapters in the medical literature, covering topics in epilepsy, psychiatry, medicine, pharmacology, research design, outcome assessment, and compliance. Besides her research on medication compliance, she has also developed several quality of life instruments. She is a frequent lecturer and consultant on these topics.
Ms. Cramer's books include Patient Compliance in Medical Practice and Clinical Trials; Alcohol and Seizures; Quantitative Assessment in Epilepsy Care; Quality of Life and Pharmacoeconomics; and Patient Recruitment in Clinical Trials.
She serves on the editorial board of Epilepsy and Behavior; chairs the Board of Trustees at the Lenox Fund; and is past treasurer of the American Epilepsy Society. Ms. Cramer also serves on the boards of directors of the Society for Clinical Trials and the American Epilepsy Society. She received the International Ambassdor Award and the U.S. Service Award from international epilepsy societies for her research.
Suzanne Bennett Johnson, Ph.D.
Dr. Johnson is a Professor and Chair in the Department of Medical Humanities and Social Sciences at Florida State University College of Medicine. Dr. Johnson has worked since 1980 on the relationship between behavioral and health projects funded by NIH.
She has developed sophisticated methods for assessing compliance behaviors relevant to complex medical regimens, and has developed age-appropriate guidelines to assist families in transferring management of the disease from parent to child. Dr. Johnson has also conducted research examining the effects of stress on disease onset and course, as well as studies assessing the psychosocial impact of screening programs to identify at-risk individuals before disease onset.
Dr. Johnson has authored numerous journal articles and book chapters, and has edited books. She has received many academic teaching and research awards.
Aidan Long, M.D., F.R.C.P.C.
Dr. Long is the Clinical Director of Allergy and the Training Program Director in Allergy and Immunology at Massachusetts General Hospital (MGH) in Boston. He is Assistant Professor of Medicine at Harvard Medical School. He is principal of the MGH site of Partners Asthma Center. He attended medical school and undertook residency training in Internal Medicine in Ireland before fellowship training in Allergy and Immunology at McMaster University in Hamilton Ontario Canada. He was on the faculty of Tufts-new England Medical Center in Boston before assuming his current position at MGH.
Over the years his research interests have evolved form molecular studies of immunoglobulin variable region gene usage in autoimmune diseases and allergic diseases to clinical asthma epidemiology, management, outcomes measurement and issues related to adherence.
Michael B. Nichol, Ph.D
Dr. Michael Nichol is Associate Professor and Chair of the Department of Pharmaceutical and Economics Policy at the University of Southern California School of Pharmacy in Los Angeles. He also holds joint appointments at the Leonard Davis School of Gerontology and the School of Policy, Planning and Development.
Dr. Nichol's previous positions include Executive Director of the Western Oregon Health Systems Agency, and Planner at the Oregon State Health Planning Agency. He received a university teaching award for classroom innovations and an award conferred by the American Society of Health-System Pharmacists Foundation for excellence in research. Dr. Nichol has also authored several publications.
In addition, he has served on the Board of Directors of several southern California research and health service organizations. Dr. Nichol has served as a consultant to numerous pharmaceutical companies. He has also been awarded the QSAD Centurion Chair at the School of Pharmacy.
Phil Oppenheimer, Pharm.D.
Dr. Oppenheimer is Dean of the School of Pharmacy at the University of the Pacific. For 24 years, Dean Oppenheimer was a faculty member at the University of Southern California School of Pharmacy where he taught Pediatrics, Infectious Diseases, and OTC Drug Therapy. During his tenure at USC, he attracted over $1 million in grants and published the material in both medical and pharmacy literature. He also served as Associate Editor of Pharmacy Today.
Dr. Oppenheimer has been active in state and national pharmacy associations. He is a member of the American Pharmaceutical Association, American Society of Hospital Pharmacists, and California Pharmacists Association. He is the recipient of the American Society of Hospital Pharmacy Foundation's Research in Practice Award, California Legislator Leadership Award, and the National Association of Community Pharmacists Leadership Award.
Michael A. Rapoff, Ph.D.
Michael Rapoff received his Ph.D in Developmental and Child Psychology in 1980 from the University of Kansas and completed a two year post-doctoral internship in Behavioral Pediatrics at the University of Kansas Medical Center. Dr. Rapoff is currently Ralph L. Smith Professor of Pediatrics and Chief of the Behavioral Pediatrics division in the Department of Pediatrics at the University of Kansas Medical Center. Dr. Rapoff is a Fellow of the American Psychological Association and is a licensed psychologist in Kansas and Missouri and is listed in the National Registry of Health Service Providers in Psychology.
His research interests over the past 25 years has focused on psychosocial issues affecting children and adolescents with chronic diseases, including adherence to medical regimens, pain, and psychosocial adjustment. He has been funded by NIH and Maternal and Child Health to evaluate strategies for improving adherence to medical regimens for children with asthma and juvenile rheumatoid arthritis (JRA) and by the Arthritis Foundation for evaluating a cognitive-behavioral pain management program for children and adolescents with JRA
Dr. Rapoff has 71 publications in journals or books, including a single-authored book published in 1999 on pediatric medical adherence ( Adherence to Pediatric Medical Regimens, New York: Kluwer/Plenum). In 2003, Dr. Rapoff received the Distinguished Scholar Award from the Association of Rheumatology Health Professionals, a division of the American College of Rheumatology, in recognition of outstanding rheumatology scholarship. Also in 2003, Dr. Rapoff was elected as a Fellow in the Society of Pediatric Psychology, Division 54 of the American Psychological Association. Dr. Rapoff is currently funded by NIH to evaluate the efficacy of a computer-based CD-ROM program (Headstrong) for treating chronic headaches in children. In addition to his research, Dr. Rapoff trains clinical psychology students in health psychology and pediatric psychology and teaches residents and medical students. He also sees patients once per week in his Behavioral Pediatrics Outreach Clinic in Lawrence, KS.
Sebastian Schneeweiss, M.D., Sc.D.
Dr. Sebastian Schneeweiss is Associate Professor of Medicine and Epidemiology at Harvard Medical School. He is also Director for Drug Evaluation and Outcomes Research in the Division of Pharmacoepidemiology and Pharmacoeconomics at the Brigham & Women's Hospital in Boston. He received an M.D. in 1992 from the Ludwigs-Maximilians-University in Munich and a Sc.D. degree in Epidemiology and Pharmaceutical Outcomes Research from Harvard.
Dr. Schneeweiss served on the faculty of University of Munich Medical School before leading a research group in Boston. His current NIH-funded research in pharmacoepidemiology and pharmaceutical outcomes research focuses on clinical and economic consequences of drug reimbursement restrictions and the safety of pharmaceuticals and biotech products, using large claims databases. Developing and testing new pharmacoepidemiologic methods using large computerized databases are an important part of his research and teaching.
Dr. Schneeweiss has published in numerous scientific journals, including the New England Journal of Medicine. He is a Fellow of the American College of Epidemiology and the International Society for Pharmacoepidemiology.
Eyal Shemesh, M.D.
Eyal Shemesh is assistant professor of Psychiatry and Pediatrics at Mount Sinai Medical Center in New York. Dr. Shemesh was trained in Hadassah medical School in Jerusalem, Israel. Following medical school training, Dr. Shemesh served for 5 years as a military physician. As a medical officer and the head of operations of a large clinical facility, he got a service medal for having been able to improve officer's attendance in clinics. Following this army service experience, he trained in the Mount Sinai "Triple Board" program as a pediatrician, psychiatrist, and a child psychiatrist. In his faculty position, Dr. Shemesh has been funded to conduct research in the interface between psychiatric and medical disorders, with nonadherence as the important outcome, in two principal patient groups: children who had a solid organ transplant, and adults who had a myocardial infarction. The work has concentrated on developing objective tests to identify nonadherence in these patient groups, evaluating adherence to specific medications, and evaluating the impact of psychiatric disorders on nonadherence.
Apart from his full time research position at Mount Sinai, Dr. Shemesh and his group collaborate clinically with a pediatric transplant clinic at Mount Sinai, a general pediatric clinic in Harlem, and a cardiology clinic in Elmhurst, Queens. In all of these, the intent is to develop service delivery systems that will, hopefully, improve adherence and enhance patients' access to mental health care by positioning a mental health team in the clinic setting, and by offering screening options.
Dr. Shemesh has won several awards for this work, including the American Academy of Child and Adolescent Psychiatry's "Presidential Scholar" award, and the Mount Sinai School of Medicine's Dr. Harold and Golden Lamport award for clinical research. His publications include peer-reviewed manuscripts exploring nonadherence to medications in these patient groups, reviews, and also two chapters in medical textbooks that are devoted to the management of nonadherence to medications.
Mark Vanelli, M.D., M.H.S.
Mark Vanelli, M.D. is Chief Medical Officer at Adheris and a Lecturer in Psychiatry at Harvard Medical School. He received a B.A. cum laude in History and Science at Harvard University in 1980, and a master's degree in public health at the Johns Hopkins School of Hygiene and Public Health in 1983. Dr. Vanelli completed his M.D. at Brown University School of Medicine in Providence in 1987 and his psychiatry residency at Harvard Medical School at the Cambridge Hospital.
From 1991 to 1998 Dr. Vanelli served as medical director of an inpatient psychiatric ward serving the indigent and persistently mentally ill. He became interested in medication adherence based on his clinical experience with readmitting to the hospital a large number of patients who had prematurely discontinued their medication in the community.
Dr. Vanelli is a faculty member at Harvard Medical School; a Diplomate, American Board of Psychiatry and Neurology; and a past member of the American Public Health Association.
In addition, Dr. Vanelli has published in the areas of medical leadership and medication adherence. He has worked as a consultant with international health care organizations, pharmaceutical manufacturers, and provider groups.
|
|
|
